Lenacapavir from Gilead Sciences has shown promise when dosed even more widely apart - only once a year...

We've had our Eyes On recent data releases, commercial strategy updates, and some FDA updates. What caught your Eye last week?

Some of the highlights include AI medical advancements, strategic industry movements, regulatory updates, & challenges within the pharma ...